Biochempharm Revolutionizes Bacteriophage Production, Introduces Phage Award in Celebration

Biochempharm, a renowned Georgian biopharmaceutical company, has achieved a landmark feat in the biotech industry. The company has successfully modernized its historical bacteriophage production enterprise, which dates back to 1934, in line with European standards, propelling forward its capacities in research, drug development, and manufacturing.

Nestled in the historic Bacteriophage Institute in Tbilisi, the freshly refurbished "Biochemfarm" plant emerges as a pioneer in the South Caucasus region. It stands as the first facility in the area to master the production of unencapsulated, sterile forms of drugs and to manage a comprehensive production cycle, which includes the formulation of Active Pharmaceutical Ingredients (APIs). In addition to that, the plant handles both primary and secondary packaging of the medications.

To commemorate this monumental accomplishment, Biochempharm has initiated the "Phage Award". This award was granted to their esteemed partners in celebration of the fruitful collaborations.

Rati Golijashvili, the General Manager of Biochemfarm, conveyed his gratitude to the partners saying, "Our heartfelt thanks to all our local and global partners for their steadfast support, which includes esteemed entities like the European Union, the European Bank for Reconstruction and Development (EBRD), the 'Produce in Georgia' program, the United Nations Food and Agriculture Organization (FAO), ProCredit Bank, and the Georgian Innovation and Technology Agency (GITA). The 'Phage Award' was conceived and conferred upon our treasured partners, recognizing their crucial roles in battling antibiotic resistance and propelling the progress of phage technology."

This article lays special emphasis on the Georgian Innovation and Technology Agency (GITA). A collaborative memorandum has been executed with GITA to foster the creation of innovative biopharmaceutical and biotechnological products. These promising innovations aspire to counter the formidable global issue of antimicrobial resistance. We applaud the dedication and contributions of the GITA team, led by the Chairman of the Innovation and Technology Agency, Avtandil Kasradze, for their pivotal role in advancing phage therapy. We also share images documenting the momentous award ceremony and the signing of the partnership memorandum.

With joint efforts like these, we see promising strides in the critical fight against antibiotic resistance.